<DOC>
	<DOCNO>NCT02733614</DOCNO>
	<brief_summary>18-week , crossover , double-blind , randomize , placebo control proof-of-concept study ass efficacy safety SRX246 ( 160 mg bid ) v placebo 52 adult veteran civilian primary diagnosis PTSD . Subjects randomly assign double-blind fashion 2 group crossover design . The first group receive SRX246 8 week follow 8 week placebo , second group receive placebo 8 week follow 8 week SRX246 . Both group engage 7-day washout period treatment . Subjects assess baseline every 2 week trial use CAPS .</brief_summary>
	<brief_title>Proof-of-concept Study Assess Efficacy Safety SRX246 Adults With PTSD</brief_title>
	<detailed_description />
	<mesh_term>Stress Disorders , Post-Traumatic</mesh_term>
	<mesh_term>SRX246</mesh_term>
	<criteria>Medically stable , current diagnosis PTSD Medically unstable</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>